ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antibody and Recombinant Protein CDMO Market Research Report 2025
Published Date: February 2025
|
Report Code: QYRE-Auto-9N10014
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Antibody and Recombinant Protein CDMO Market Research Report 2022
BUY CHAPTERS

Global Antibody and Recombinant Protein CDMO Market Research Report 2025

Code: QYRE-Auto-9N10014
Report
February 2025
Pages:105
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Batavia Biosciences
Grifols S A
HALIX
Biovian
Catalent
Goodwin Biotechnology
Merck
Eurogentec S.A
Vetter
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Etinpro (Beijing) Co
Cerbios-Pharma SA

Antibody and Recombinant Protein CDMO Market Size

The global market for Antibody and Recombinant Protein CDMO was valued at US$ 59130 million in the year 2024 and is projected to reach a revised size of US$ 94330 million by 2031, growing at a CAGR of 7.0% during the forecast period.

Antibody and Recombinant Protein CDMO Market

Antibody and Recombinant Protein CDMO Market

North American market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Antibody and Recombinant Protein CDMO is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Antibody and Recombinant Protein CDMO in Pharmaceutical Company is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Antibody and Recombinant Protein CDMO include Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck, Hangzhou Hs-biopharm, Wuxibiologics, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody and Recombinant Protein CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody and Recombinant Protein CDMO.
The Antibody and Recombinant Protein CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody and Recombinant Protein CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody and Recombinant Protein CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Antibody and Recombinant Protein CDMO Market Report

Report Metric Details
Report Name Antibody and Recombinant Protein CDMO Market
Accounted market size in year US$ 59130 million
Forecasted market size in 2031 US$ 94330 million
CAGR 7.0%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Antibody CDMO
  • Recombinant Protein CDMO
Segment by Application
  • Pharmaceutical Company
  • Biotechnology Company
  • Generic Company
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck, Hangzhou Hs-biopharm, Wuxibiologics, Bioinnobio, Thousand Oaks Biopharmaceuticals, Eurogentec, HJB, Bibo Pharma, MabPlex International, Genscriptprobio, Vetter, Etinpro (Beijing) Co, Boehringer Ingelheim BioXcellence, Lonza, 3SBio Inc, Porton
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Antibody and Recombinant Protein CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Antibody and Recombinant Protein CDMO Market growing?

Ans: The Antibody and Recombinant Protein CDMO Market witnessing a CAGR of 7.0% during the forecast period 2025-2031.

What is the Antibody and Recombinant Protein CDMO Market size in 2031?

Ans: The Antibody and Recombinant Protein CDMO Market size in 2031 will be US$ 94330 million.

Who are the main players in the Antibody and Recombinant Protein CDMO Market report?

Ans: The main players in the Antibody and Recombinant Protein CDMO Market are Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck, Hangzhou Hs-biopharm, Wuxibiologics, Bioinnobio, Thousand Oaks Biopharmaceuticals, Eurogentec, HJB, Bibo Pharma, MabPlex International, Genscriptprobio, Vetter, Etinpro (Beijing) Co, Boehringer Ingelheim BioXcellence, Lonza, 3SBio Inc, Porton

What are the Application segmentation covered in the Antibody and Recombinant Protein CDMO Market report?

Ans: The Applications covered in the Antibody and Recombinant Protein CDMO Market report are Pharmaceutical Company, Biotechnology Company, Generic Company

What are the Type segmentation covered in the Antibody and Recombinant Protein CDMO Market report?

Ans: The Types covered in the Antibody and Recombinant Protein CDMO Market report are Antibody CDMO, Recombinant Protein CDMO

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Antibody CDMO
1.2.3 Recombinant Protein CDMO
1.3 Market by Application
1.3.1 Global Antibody and Recombinant Protein CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Generic Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody and Recombinant Protein CDMO Market Perspective (2020-2031)
2.2 Global Antibody and Recombinant Protein CDMO Growth Trends by Region
2.2.1 Global Antibody and Recombinant Protein CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody and Recombinant Protein CDMO Historic Market Size by Region (2020-2025)
2.2.3 Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2026-2031)
2.3 Antibody and Recombinant Protein CDMO Market Dynamics
2.3.1 Antibody and Recombinant Protein CDMO Industry Trends
2.3.2 Antibody and Recombinant Protein CDMO Market Drivers
2.3.3 Antibody and Recombinant Protein CDMO Market Challenges
2.3.4 Antibody and Recombinant Protein CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue
3.1.1 Global Top Antibody and Recombinant Protein CDMO Players by Revenue (2020-2025)
3.1.2 Global Antibody and Recombinant Protein CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Antibody and Recombinant Protein CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody and Recombinant Protein CDMO Revenue
3.4 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio
3.4.1 Global Antibody and Recombinant Protein CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody and Recombinant Protein CDMO Revenue in 2024
3.5 Global Key Players of Antibody and Recombinant Protein CDMO Head office and Area Served
3.6 Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application
3.7 Global Key Players of Antibody and Recombinant Protein CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody and Recombinant Protein CDMO Breakdown Data by Type
4.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Type (2020-2025)
4.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2026-2031)
5 Antibody and Recombinant Protein CDMO Breakdown Data by Application
5.1 Global Antibody and Recombinant Protein CDMO Historic Market Size by Application (2020-2025)
5.2 Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody and Recombinant Protein CDMO Market Size (2020-2031)
6.2 North America Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)
6.4 North America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody and Recombinant Protein CDMO Market Size (2020-2031)
7.2 Europe Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)
7.4 Europe Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size (2020-2031)
8.2 Asia-Pacific Antibody and Recombinant Protein CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody and Recombinant Protein CDMO Market Size (2020-2031)
9.2 Latin America Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)
9.4 Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size (2020-2031)
10.2 Middle East & Africa Antibody and Recombinant Protein CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Batavia Biosciences
11.1.1 Batavia Biosciences Company Details
11.1.2 Batavia Biosciences Business Overview
11.1.3 Batavia Biosciences Antibody and Recombinant Protein CDMO Introduction
11.1.4 Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.1.5 Batavia Biosciences Recent Development
11.2 Grifols
11.2.1 Grifols Company Details
11.2.2 Grifols Business Overview
11.2.3 Grifols Antibody and Recombinant Protein CDMO Introduction
11.2.4 Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.2.5 Grifols Recent Development
11.3 Cerbios-Pharma SA
11.3.1 Cerbios-Pharma SA Company Details
11.3.2 Cerbios-Pharma SA Business Overview
11.3.3 Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Introduction
11.3.4 Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.3.5 Cerbios-Pharma SA Recent Development
11.4 HALIX
11.4.1 HALIX Company Details
11.4.2 HALIX Business Overview
11.4.3 HALIX Antibody and Recombinant Protein CDMO Introduction
11.4.4 HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.4.5 HALIX Recent Development
11.5 Biovian Oy
11.5.1 Biovian Oy Company Details
11.5.2 Biovian Oy Business Overview
11.5.3 Biovian Oy Antibody and Recombinant Protein CDMO Introduction
11.5.4 Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.5.5 Biovian Oy Recent Development
11.6 Catalent
11.6.1 Catalent Company Details
11.6.2 Catalent Business Overview
11.6.3 Catalent Antibody and Recombinant Protein CDMO Introduction
11.6.4 Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.6.5 Catalent Recent Development
11.7 Goodwin Biotechnology
11.7.1 Goodwin Biotechnology Company Details
11.7.2 Goodwin Biotechnology Business Overview
11.7.3 Goodwin Biotechnology Antibody and Recombinant Protein CDMO Introduction
11.7.4 Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.7.5 Goodwin Biotechnology Recent Development
11.8 Merck
11.8.1 Merck Company Details
11.8.2 Merck Business Overview
11.8.3 Merck Antibody and Recombinant Protein CDMO Introduction
11.8.4 Merck Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.8.5 Merck Recent Development
11.9 Hangzhou Hs-biopharm
11.9.1 Hangzhou Hs-biopharm Company Details
11.9.2 Hangzhou Hs-biopharm Business Overview
11.9.3 Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Introduction
11.9.4 Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.9.5 Hangzhou Hs-biopharm Recent Development
11.10 Wuxibiologics
11.10.1 Wuxibiologics Company Details
11.10.2 Wuxibiologics Business Overview
11.10.3 Wuxibiologics Antibody and Recombinant Protein CDMO Introduction
11.10.4 Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.10.5 Wuxibiologics Recent Development
11.11 Bioinnobio
11.11.1 Bioinnobio Company Details
11.11.2 Bioinnobio Business Overview
11.11.3 Bioinnobio Antibody and Recombinant Protein CDMO Introduction
11.11.4 Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.11.5 Bioinnobio Recent Development
11.12 Thousand Oaks Biopharmaceuticals
11.12.1 Thousand Oaks Biopharmaceuticals Company Details
11.12.2 Thousand Oaks Biopharmaceuticals Business Overview
11.12.3 Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Introduction
11.12.4 Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.12.5 Thousand Oaks Biopharmaceuticals Recent Development
11.13 Eurogentec
11.13.1 Eurogentec Company Details
11.13.2 Eurogentec Business Overview
11.13.3 Eurogentec Antibody and Recombinant Protein CDMO Introduction
11.13.4 Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.13.5 Eurogentec Recent Development
11.14 HJB
11.14.1 HJB Company Details
11.14.2 HJB Business Overview
11.14.3 HJB Antibody and Recombinant Protein CDMO Introduction
11.14.4 HJB Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.14.5 HJB Recent Development
11.15 Bibo Pharma
11.15.1 Bibo Pharma Company Details
11.15.2 Bibo Pharma Business Overview
11.15.3 Bibo Pharma Antibody and Recombinant Protein CDMO Introduction
11.15.4 Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.15.5 Bibo Pharma Recent Development
11.16 MabPlex International
11.16.1 MabPlex International Company Details
11.16.2 MabPlex International Business Overview
11.16.3 MabPlex International Antibody and Recombinant Protein CDMO Introduction
11.16.4 MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.16.5 MabPlex International Recent Development
11.17 Genscriptprobio
11.17.1 Genscriptprobio Company Details
11.17.2 Genscriptprobio Business Overview
11.17.3 Genscriptprobio Antibody and Recombinant Protein CDMO Introduction
11.17.4 Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.17.5 Genscriptprobio Recent Development
11.18 Vetter
11.18.1 Vetter Company Details
11.18.2 Vetter Business Overview
11.18.3 Vetter Antibody and Recombinant Protein CDMO Introduction
11.18.4 Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.18.5 Vetter Recent Development
11.19 Etinpro (Beijing) Co
11.19.1 Etinpro (Beijing) Co Company Details
11.19.2 Etinpro (Beijing) Co Business Overview
11.19.3 Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Introduction
11.19.4 Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.19.5 Etinpro (Beijing) Co Recent Development
11.20 Boehringer Ingelheim BioXcellence
11.20.1 Boehringer Ingelheim BioXcellence Company Details
11.20.2 Boehringer Ingelheim BioXcellence Business Overview
11.20.3 Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Introduction
11.20.4 Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.20.5 Boehringer Ingelheim BioXcellence Recent Development
11.21 Lonza
11.21.1 Lonza Company Details
11.21.2 Lonza Business Overview
11.21.3 Lonza Antibody and Recombinant Protein CDMO Introduction
11.21.4 Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.21.5 Lonza Recent Development
11.22 3SBio Inc
11.22.1 3SBio Inc Company Details
11.22.2 3SBio Inc Business Overview
11.22.3 3SBio Inc Antibody and Recombinant Protein CDMO Introduction
11.22.4 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.22.5 3SBio Inc Recent Development
11.23 Porton
11.23.1 Porton Company Details
11.23.2 Porton Business Overview
11.23.3 Porton Antibody and Recombinant Protein CDMO Introduction
11.23.4 Porton Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025)
11.23.5 Porton Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Batavia Biosciences
Grifols S A
HALIX
Biovian
Catalent
Goodwin Biotechnology
Merck
Eurogentec S.A
Vetter
Boehringer Ingelheim BioXcellence
Lonza
3SBio Inc
Porton
Hangzhou Hs-biopharm
Wuxibiologics
Bioinnobio
Thousand Oaks Biopharmaceuticals
HJB
Bibo Pharma
MabPlex International
Genscriptprobio
Etinpro (Beijing) Co
Cerbios-Pharma SA
List of Tables
 Table 1. Global Antibody and Recombinant Protein CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Antibody CDMO
 Table 3. Key Players of Recombinant Protein CDMO
 Table 4. Global Antibody and Recombinant Protein CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Antibody and Recombinant Protein CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Antibody and Recombinant Protein CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Antibody and Recombinant Protein CDMO Market Share by Region (2020-2025)
 Table 8. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Antibody and Recombinant Protein CDMO Market Share by Region (2026-2031)
 Table 10. Antibody and Recombinant Protein CDMO Market Trends
 Table 11. Antibody and Recombinant Protein CDMO Market Drivers
 Table 12. Antibody and Recombinant Protein CDMO Market Challenges
 Table 13. Antibody and Recombinant Protein CDMO Market Restraints
 Table 14. Global Antibody and Recombinant Protein CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Antibody and Recombinant Protein CDMO Market Share by Players (2020-2025)
 Table 16. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2024)
 Table 17. Ranking of Global Top Antibody and Recombinant Protein CDMO Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Antibody and Recombinant Protein CDMO Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Antibody and Recombinant Protein CDMO, Headquarters and Area Served
 Table 20. Global Key Players of Antibody and Recombinant Protein CDMO, Product and Application
 Table 21. Global Key Players of Antibody and Recombinant Protein CDMO, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Antibody and Recombinant Protein CDMO Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2020-2025)
 Table 25. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Type (2026-2031)
 Table 27. Global Antibody and Recombinant Protein CDMO Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Application (2020-2025)
 Table 29. Global Antibody and Recombinant Protein CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Antibody and Recombinant Protein CDMO Revenue Market Share by Application (2026-2031)
 Table 31. North America Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Batavia Biosciences Company Details
 Table 47. Batavia Biosciences Business Overview
 Table 48. Batavia Biosciences Antibody and Recombinant Protein CDMO Product
 Table 49. Batavia Biosciences Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 50. Batavia Biosciences Recent Development
 Table 51. Grifols Company Details
 Table 52. Grifols Business Overview
 Table 53. Grifols Antibody and Recombinant Protein CDMO Product
 Table 54. Grifols Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 55. Grifols Recent Development
 Table 56. Cerbios-Pharma SA Company Details
 Table 57. Cerbios-Pharma SA Business Overview
 Table 58. Cerbios-Pharma SA Antibody and Recombinant Protein CDMO Product
 Table 59. Cerbios-Pharma SA Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 60. Cerbios-Pharma SA Recent Development
 Table 61. HALIX Company Details
 Table 62. HALIX Business Overview
 Table 63. HALIX Antibody and Recombinant Protein CDMO Product
 Table 64. HALIX Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 65. HALIX Recent Development
 Table 66. Biovian Oy Company Details
 Table 67. Biovian Oy Business Overview
 Table 68. Biovian Oy Antibody and Recombinant Protein CDMO Product
 Table 69. Biovian Oy Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 70. Biovian Oy Recent Development
 Table 71. Catalent Company Details
 Table 72. Catalent Business Overview
 Table 73. Catalent Antibody and Recombinant Protein CDMO Product
 Table 74. Catalent Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 75. Catalent Recent Development
 Table 76. Goodwin Biotechnology Company Details
 Table 77. Goodwin Biotechnology Business Overview
 Table 78. Goodwin Biotechnology Antibody and Recombinant Protein CDMO Product
 Table 79. Goodwin Biotechnology Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 80. Goodwin Biotechnology Recent Development
 Table 81. Merck Company Details
 Table 82. Merck Business Overview
 Table 83. Merck Antibody and Recombinant Protein CDMO Product
 Table 84. Merck Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 85. Merck Recent Development
 Table 86. Hangzhou Hs-biopharm Company Details
 Table 87. Hangzhou Hs-biopharm Business Overview
 Table 88. Hangzhou Hs-biopharm Antibody and Recombinant Protein CDMO Product
 Table 89. Hangzhou Hs-biopharm Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 90. Hangzhou Hs-biopharm Recent Development
 Table 91. Wuxibiologics Company Details
 Table 92. Wuxibiologics Business Overview
 Table 93. Wuxibiologics Antibody and Recombinant Protein CDMO Product
 Table 94. Wuxibiologics Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 95. Wuxibiologics Recent Development
 Table 96. Bioinnobio Company Details
 Table 97. Bioinnobio Business Overview
 Table 98. Bioinnobio Antibody and Recombinant Protein CDMO Product
 Table 99. Bioinnobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 100. Bioinnobio Recent Development
 Table 101. Thousand Oaks Biopharmaceuticals Company Details
 Table 102. Thousand Oaks Biopharmaceuticals Business Overview
 Table 103. Thousand Oaks Biopharmaceuticals Antibody and Recombinant Protein CDMO Product
 Table 104. Thousand Oaks Biopharmaceuticals Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 105. Thousand Oaks Biopharmaceuticals Recent Development
 Table 106. Eurogentec Company Details
 Table 107. Eurogentec Business Overview
 Table 108. Eurogentec Antibody and Recombinant Protein CDMO Product
 Table 109. Eurogentec Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 110. Eurogentec Recent Development
 Table 111. HJB Company Details
 Table 112. HJB Business Overview
 Table 113. HJB Antibody and Recombinant Protein CDMO Product
 Table 114. HJB Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 115. HJB Recent Development
 Table 116. Bibo Pharma Company Details
 Table 117. Bibo Pharma Business Overview
 Table 118. Bibo Pharma Antibody and Recombinant Protein CDMO Product
 Table 119. Bibo Pharma Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 120. Bibo Pharma Recent Development
 Table 121. MabPlex International Company Details
 Table 122. MabPlex International Business Overview
 Table 123. MabPlex International Antibody and Recombinant Protein CDMO Product
 Table 124. MabPlex International Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 125. MabPlex International Recent Development
 Table 126. Genscriptprobio Company Details
 Table 127. Genscriptprobio Business Overview
 Table 128. Genscriptprobio Antibody and Recombinant Protein CDMO Product
 Table 129. Genscriptprobio Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 130. Genscriptprobio Recent Development
 Table 131. Vetter Company Details
 Table 132. Vetter Business Overview
 Table 133. Vetter Antibody and Recombinant Protein CDMO Product
 Table 134. Vetter Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 135. Vetter Recent Development
 Table 136. Etinpro (Beijing) Co Company Details
 Table 137. Etinpro (Beijing) Co Business Overview
 Table 138. Etinpro (Beijing) Co Antibody and Recombinant Protein CDMO Product
 Table 139. Etinpro (Beijing) Co Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 140. Etinpro (Beijing) Co Recent Development
 Table 141. Boehringer Ingelheim BioXcellence Company Details
 Table 142. Boehringer Ingelheim BioXcellence Business Overview
 Table 143. Boehringer Ingelheim BioXcellence Antibody and Recombinant Protein CDMO Product
 Table 144. Boehringer Ingelheim BioXcellence Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 145. Boehringer Ingelheim BioXcellence Recent Development
 Table 146. Lonza Company Details
 Table 147. Lonza Business Overview
 Table 148. Lonza Antibody and Recombinant Protein CDMO Product
 Table 149. Lonza Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 150. Lonza Recent Development
 Table 151. 3SBio Inc Company Details
 Table 152. 3SBio Inc Business Overview
 Table 153. 3SBio Inc Antibody and Recombinant Protein CDMO Product
 Table 154. 3SBio Inc Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 155. 3SBio Inc Recent Development
 Table 156. Porton Company Details
 Table 157. Porton Business Overview
 Table 158. Porton Antibody and Recombinant Protein CDMO Product
 Table 159. Porton Revenue in Antibody and Recombinant Protein CDMO Business (2020-2025) & (US$ Million)
 Table 160. Porton Recent Development
 Table 161. Research Programs/Design for This Report
 Table 162. Key Data Information from Secondary Sources
 Table 163. Key Data Information from Primary Sources
 Table 164. Authors List of This Report


List of Figures
 Figure 1. Antibody and Recombinant Protein CDMO Picture
 Figure 2. Global Antibody and Recombinant Protein CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Antibody and Recombinant Protein CDMO Market Share by Type: 2024 VS 2031
 Figure 4. Antibody CDMO Features
 Figure 5. Recombinant Protein CDMO Features
 Figure 6. Global Antibody and Recombinant Protein CDMO Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Antibody and Recombinant Protein CDMO Market Share by Application: 2024 VS 2031
 Figure 8. Pharmaceutical Company Case Studies
 Figure 9. Biotechnology Company Case Studies
 Figure 10. Generic Company Case Studies
 Figure 11. Antibody and Recombinant Protein CDMO Report Years Considered
 Figure 12. Global Antibody and Recombinant Protein CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 13. Global Antibody and Recombinant Protein CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Antibody and Recombinant Protein CDMO Market Share by Region: 2024 VS 2031
 Figure 15. Global Antibody and Recombinant Protein CDMO Market Share by Players in 2024
 Figure 16. Global Top Antibody and Recombinant Protein CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody and Recombinant Protein CDMO as of 2024)
 Figure 17. The Top 10 and 5 Players Market Share by Antibody and Recombinant Protein CDMO Revenue in 2024
 Figure 18. North America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 19. North America Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)
 Figure 20. United States Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)
 Figure 24. Germany Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. France Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. U.K. Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Italy Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Russia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Nordic Countries Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Antibody and Recombinant Protein CDMO Market Share by Region (2020-2031)
 Figure 32. China Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Japan Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. South Korea Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. Southeast Asia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. India Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Australia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)
 Figure 40. Mexico Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Brazil Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Antibody and Recombinant Protein CDMO Market Share by Country (2020-2031)
 Figure 44. Turkey Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Saudi Arabia Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. UAE Antibody and Recombinant Protein CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. Batavia Biosciences Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 48. Grifols Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 49. Cerbios-Pharma SA Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 50. HALIX Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 51. Biovian Oy Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 52. Catalent Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 53. Goodwin Biotechnology Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 54. Merck Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 55. Hangzhou Hs-biopharm Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 56. Wuxibiologics Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 57. Bioinnobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 58. Thousand Oaks Biopharmaceuticals Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 59. Eurogentec Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 60. HJB Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 61. Bibo Pharma Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 62. MabPlex International Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 63. Genscriptprobio Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 64. Vetter Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 65. Etinpro (Beijing) Co Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 66. Boehringer Ingelheim BioXcellence Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 67. Lonza Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 68. 3SBio Inc Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 69. Porton Revenue Growth Rate in Antibody and Recombinant Protein CDMO Business (2020-2025)
 Figure 70. Bottom-up and Top-down Approaches for This Report
 Figure 71. Data Triangulation
 Figure 72. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Chrysalis Oil Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26N13078
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Eucommia Ulmoides Extract Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3L13782
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global MRSA Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-26S13718
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Global Ferrous Citrate Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-16S12875
Fri Mar 21 00:00:00 UTC 2025

$5800

Enterprise User

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions